Literature DB >> 18562408

Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.

C Akkaya1, B Kaya, Z Kotan, A Sarandol, C Ersoy, S Kirli.   

Abstract

Schizophrenia is a chronic and debilitating psychotic mental disorder that affects about 1% of the world's population. Antipsychotic drugs are the mainstay of treatment in schizophrenia. Hyperprolactinemia, which is a common side effect of typical antipsychotics, is also associated with the use of some of the newer atypical agents. Antipsychotics may enhance prolactinoma growth as manifested by an increase in serum prolactin concentration. Prolactin-secreting pituitary adenomas possibly related with antipsychotics have been described in the literature. To our knowledge, this is the first series of cases showing a possible relation between pituitary adenomas and amisulpride treatment in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562408     DOI: 10.1177/0269881108091252

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  4 in total

Review 1.  Curious cases: Acromegaly and schizophrenia: an incidental association?

Authors:  Pedro Iglesias; Carmen Bernal; Juan J Díez
Journal:  Schizophr Bull       Date:  2014-03-06       Impact factor: 9.306

2.  New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature.

Authors:  Elvis Henrique Santos Andrade; Pedro Mario Pan; Paula F Ramalho da Silva; Ary Gadelha
Journal:  Case Rep Med       Date:  2010-11-10

3.  Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.

Authors:  Zeynep Kotan; Berrin Ertepe; Cengiz Akkaya; Emre Sarandol; Güven Ozkaya; Selçuk Kirli
Journal:  Ther Adv Psychopharmacol       Date:  2011-12

Review 4.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.